Fereydooni Arash, Satam Keyuree, Dossabhoy Shernaz, Trogolo-Franco Claudia, Sorondo Sabina, Arya Shipra, Ullery Brant W, Lee Jason T
Division of Vascular & Endovascular Surgery, Department of Surgery, Stanford University, Palo Alto, CA.
Oregon Vascular Specialists, Portland, OR.
J Vasc Surg. 2025 Apr;81(4):856-865.e1. doi: 10.1016/j.jvs.2024.11.020. Epub 2024 Nov 26.
Hostile aortic neck anatomy is associated with loss of proximal seal and increased late reinterventions. Although both EndoSuture aneurysm repair (ESAR) and fenestrated endovascular aortic repair (FEVAR) are commercially available options for treatment of short neck aneurysms, branch vessel patency is a potential tradeoff for improved seal with FEVAR owing to the incorporation of renovisceral vessels. This study compares the performance of ESAR vs FEVAR in hostile aortic necks.
Patients who underwent elective ESAR or FEVAR for hostile neck AAAs at a single center from 2012 to 2024 were reviewed retrospectively. Exclusion criteria included pararenal or thoracoabdominal aortic aneurysm, off-label modifications, and nonstandard FEVAR configurations. Propensity matching weights were generated based on age, year of operation, preoperative estimated glomerular filtration rate, neck length, neck diameter, and infrarenal angulation. Rates of survival, reintervention, dialysis, chronic kidney disease stage progression, type IA endoleak (EL), and sac regression (>5 mm) were assessed at latest follow-up.
Of 391 patients, 60 with ESAR and 207 with FEVAR were included. FEVAR patients were younger (74.4 years vs 79.8 years; P < .001) with larger neck diameters (25.0 mm vs 23.6 mm; P = .016), shorter neck length (5.0 mm vs 9.8 mm; P < .001), and decreased infrarenal angulation (20° vs 40°; P < .001). After propensity score-adjusted regression (58 ESAR, 169 FEVAR), FEVAR, compared with ESAR, was associated with decreased IA EL (hazard ratio, 0.341; 95% confidence interval [CI], 0.061-0.72; P = .031) and increased sac regression (hazard ratio, 3.92; 95% CI, 1.25-5.14; P = .02). Notably, FEVAR was associated with increased 1-year aneurysm-related reintervention (odds ratio, 4.33; 95% CI, 1.12-10.54; P = .046). On Kaplan-Meier analysis, FEVAR was associated with reduced freedom from reinterventions at 3 years (71.8% [95% CI, 0.63-0.78] vs 93.5% [95% CI, 0.80-0.97]; log-rank P = .019) but a trend toward improved survival at 3 years (79.15% [95% CI, 0.70-0.85] vs 61.5% [95% CI, 0.44-0.74]; log-rank P = .095). There was no significant difference in new-onset chronic dialysis between ESAR and FEVAR at 3 years (94.2% [95% CI, 0.82-0.98] vs 97.4% [95% CI, 0.93-0.99]; log-rank P = .124).
In the treatment of abdominal aortic aneurysms with hostile neck anatomy in this propensity-matched cohort, FEVAR was associated with fewer type IA ELs and greater sac regression compared with ESAR, with no detrimental impact on long-term renal function. There were more reinterventions, mostly branch related, in the FEVAR group. We await the results of the current randomized prospective trial comparing these strategies to further determine the impact of these clinical differences on aneurysm-related mortality.
主动脉颈部解剖结构不良与近端密封失败及晚期再次干预增加相关。尽管EndoSuture动脉瘤修复术(ESAR)和开窗式血管内主动脉修复术(FEVAR)都是治疗短颈动脉瘤的商业可用选择,但由于合并肾周血管,分支血管通畅可能是FEVAR改善密封效果的潜在代价。本研究比较了ESAR与FEVAR在主动脉颈部解剖结构不良患者中的性能。
回顾性分析2012年至2024年在单一中心因主动脉颈部解剖结构不良的腹主动脉瘤接受择期ESAR或FEVAR治疗的患者。排除标准包括肾旁或胸腹主动脉瘤、超适应证修改以及非标准FEVAR构型。根据年龄、手术年份、术前估计肾小球滤过率、颈部长度、颈部直径和肾下角度生成倾向匹配权重。在最新随访时评估生存、再次干预、透析、慢性肾脏病分期进展、IA型内漏(EL)和瘤囊缩小(>5 mm)的发生率。
391例患者中,60例行ESAR,207例行FEVAR。FEVAR组患者更年轻(74.4岁对79.8岁;P <.001),颈部直径更大(25.0 mm对23.6 mm;P =.016),颈部长度更短(5.0 mm对9.8 mm;P <.001),肾下角度减小(20°对40°;P <.001)。在倾向评分调整回归后(58例ESAR,169例FEVAR),与ESAR相比,FEVAR与IA型EL减少相关(风险比,0.341;95%置信区间[CI],0.061 - 0.72;P =.031),瘤囊缩小增加(风险比,3.92;95% CI,1.25 - 5.14;P =.02)。值得注意的是,FEVAR与1年动脉瘤相关再次干预增加相关(优势比,4.33;95% CI,1.12 - 10.54;P =.046)。在Kaplan-Meier分析中,FEVAR与3年时再次干预自由度降低相关(71.8% [95% CI,0.63 - 0.78]对93.5% [95% CI,0.80 - 0.97];对数秩检验P =.019),但3年时有生存改善的趋势(79.15% [95% CI,0.70 - 0.85]对61.5% [95% CI,0.44 - 0.74];对数秩检验P =.09